Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 102 (Rilotumumab) With Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma
NCT01105390Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Apr 2010
- Primary completion
- May 2011
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 2, open-label, single-arm trial of rilotumumab in malignant pleural mesothelioma (MPM), sponsored by National Cancer Institute. Primary endpoint: Progression-free survival up to 3 years. Planned start Apr 2010; status: withdrawn.
02
Drugs
rilotumumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT01105390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01105390.